Oruç Yunusoğlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Oruç Yunusoğlu has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Mustafa Enes Demirel
Department of Emergency Medicine, Medical Faculty, Bolu Abant İzzet Baysal University
3 shared publications Shabnam Allahverdiyeva
3 shared publications- Yavuz Yardım
Department of Analytical Chemistry, Faculty of Pharmacy, Van Yuzuncu Yil University, Van, Turkey
3 shared publications Canan Akünal Türel
Department of Neurology, Faculty of Medicine, Bolu Abant Izzet Baysal University, Bolu, Turkey
2 shared publications- Ertuğrul Keskin
Adıyaman University, Faculty of Pharmacy, Department of Analytical Chemistry, Adıyaman, Türkiye
2 shared publications - İrEm Kalfa
Bolu Abant İzzet Baysal University
2 shared publications
Latest Publications
- 21 May 2026
- Published by Istanbul University in İstanbul Journal of Pharmacy
- Vol. 56 (1) , 80-104
Comprehensive Analysis of Oleuropein: Current Evidence on Pharmacological Activities, Therapeutic Applications and Translational Perspectives
The beneficial effects of natural plant polyphenols on human health have been extensively evaluated in numerous scientific studies. Oleuropein, a phenolic compound and ester of elenolic acid and hydroxytyrosol (3,4-dihydroxyphenylethanol), is present in various parts of the olive tree (Olea europaea L.) and has garnered significant scientific interest due to its broad therapeutic profile. An updated and comprehensive review of the existing literature was conducted using databases such as Scopus, PubMed/MEDLINE, Embase, ScienceDirect, SciELO, and SciVerse, without temporal restrictions. This review highlights recent advancements in the therapeutic potential, biological activities, and pharmacological properties of oleuropein, with emphasis on its antioxidant, anti-inflammatory, anticancer, antimicrobial, antidiabetic, antiallergic, anti-osteoporotic, anti-ageing, immunomodulatory, anti-obesity, anti-atherosclerotic, cardioprotective, hepatoprotective, nephroprotective, neuroprotective, anti-Alzheimer, antiepileptic, anti- Parkinson, anxiolytic, reproductive, gastrointestinal, respiratory, and endocrine systems. Although oleuropein is utilised as a dietary supplement in various pharmaceutical forms (e.g., tablets, capsules) for certain health conditions, no formulation has yet received regulatory approval from the European Medicines Agency or the United States Food and Drug Administration for the prevention or treatment of diseases. Ongoing comprehensive investigations continue to expand the understanding of oleuropein’s pharmacological properties, therapeutic potential, and biochemical activities. Based on the current findings, oleuropein represents a promising therapeutic agent for the prevention and treatment of various systemic diseases. However, its specific effects and underlying mechanisms in distinct pathological conditions require further validation through future preclinical and clinical studies.
- 21 May 2026
- Published by Istanbul University in İstanbul Journal of Pharmacy
- Vol. 56 (1) , 80-104
Comprehensive Analysis of Oleuropein: Current Evidence on Pharmacological Activities, Therapeutic Applications and Translational Perspectives
The beneficial effects of natural plant polyphenols on human health have been extensively evaluated in numerous scientific studies. Oleuropein, a phenolic compound and ester of elenolic acid and hydroxytyrosol (3,4-dihydroxyphenylethanol), is present in various parts of the olive tree (Olea europaea L.) and has garnered significant scientific interest due to its broad therapeutic profile. An updated and comprehensive review of the existing literature was conducted using databases such as Scopus, PubMed/MEDLINE, Embase, ScienceDirect, SciELO, and SciVerse, without temporal restrictions. This review highlights recent advancements in the therapeutic potential, biological activities, and pharmacological properties of oleuropein, with emphasis on its antioxidant, anti-inflammatory, anticancer, antimicrobial, antidiabetic, antiallergic, anti-osteoporotic, anti-ageing, immunomodulatory, anti-obesity, anti-atherosclerotic, cardioprotective, hepatoprotective, nephroprotective, neuroprotective, anti-Alzheimer, antiepileptic, anti- Parkinson, anxiolytic, reproductive, gastrointestinal, respiratory, and endocrine systems. Although oleuropein is utilised as a dietary supplement in various pharmaceutical forms (e.g., tablets, capsules) for certain health conditions, no formulation has yet received regulatory approval from the European Medicines Agency or the United States Food and Drug Administration for the prevention or treatment of diseases. Ongoing comprehensive investigations continue to expand the understanding of oleuropein’s pharmacological properties, therapeutic potential, and biochemical activities. Based on the current findings, oleuropein represents a promising therapeutic agent for the prevention and treatment of various systemic diseases. However, its specific effects and underlying mechanisms in distinct pathological conditions require further validation through future preclinical and clinical studies.
- 1 January 2026
- Published by KSU Journal of Agriculture and Nature in Kahramanmaraş Sütçü İmam Üniversitesi Tarım ve Doğa Dergisi
- Vol. 29 (1) , 15-39
Investigation of the Phytochemical Components and Antiepileptic Potential of Helichrysum pallasii (Sprengel) Ledeb. Through in vitro and in vivo Studies
This study investigated the bioactive components and in vitro and in vivo antiepileptic properties of the Helichrysum pallasii (Sprengel) Ledeb. species, which has long been used in traditional medicine in Eastern Anatolia. Pronounced antiepileptic properties of this plant were detected through in vitro antioxidant (ethanol and infusion=FCR: 112.0 and 60.0 mg GAE/gE; FRAP: 2687.5 and 1502.9 µmol Fe 2+ /gE; ORAC: 3200.7 and 2095.1 µmol Trolox Eq./gE; DPPH: IC50=440.5 and 661.0 µg ml-1; metal chelatin: IC50= 185.8 and 443.9 µg ml-1 respectively) and epilepsy-related enzyme Butyrylcholinesterase (IC50=374.5 and 817.9 µg ml-1 respectively), Acetylcholinesterase (IC50=242 and 682.0 µg ml-1 respectively) enzymes and GABA-T (IC50=350.3 and 676.4 µg ml-1 respectively) activity inhibition experiments and detailed in vivo investigations. In vivo, investigations included comparisons of the antiepileptic effects of three different dosages (60, 120, and 180 mg kg-1) of extract and infusion in a pentylenetetrazol kindling epilepsy model. It was found that the seizure scores were significantly reduced by both extracts, particularly at doses of 120 and 180 mg kg-1 (p
- 1 January 2026
- Published by KSU Journal of Agriculture and Nature in Kahramanmaraş Sütçü İmam Üniversitesi Tarım ve Doğa Dergisi
- Vol. 29 (1) , 15-39
Investigation of the Phytochemical Components and Antiepileptic Potential of Helichrysum pallasii (Sprengel) Ledeb. Through in vitro and in vivo Studies
This study investigated the bioactive components and in vitro and in vivo antiepileptic properties of the Helichrysum pallasii (Sprengel) Ledeb. species, which has long been used in traditional medicine in Eastern Anatolia. Pronounced antiepileptic properties of this plant were detected through in vitro antioxidant (ethanol and infusion=FCR: 112.0 and 60.0 mg GAE/gE; FRAP: 2687.5 and 1502.9 µmol Fe 2+ /gE; ORAC: 3200.7 and 2095.1 µmol Trolox Eq./gE; DPPH: IC50=440.5 and 661.0 µg ml-1; metal chelatin: IC50= 185.8 and 443.9 µg ml-1 respectively) and epilepsy-related enzyme Butyrylcholinesterase (IC50=374.5 and 817.9 µg ml-1 respectively), Acetylcholinesterase (IC50=242 and 682.0 µg ml-1 respectively) enzymes and GABA-T (IC50=350.3 and 676.4 µg ml-1 respectively) activity inhibition experiments and detailed in vivo investigations. In vivo, investigations included comparisons of the antiepileptic effects of three different dosages (60, 120, and 180 mg kg-1) of extract and infusion in a pentylenetetrazol kindling epilepsy model. It was found that the seizure scores were significantly reduced by both extracts, particularly at doses of 120 and 180 mg kg-1 (p
- Open Access
- 26 September 2025
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 26 (3) , 490-498
Ivermectin attenuates nicotine-induced reward-like behaviors in mice
Nicotine addiction poses a significant public health threat, particularly within the realm of emergency medicine, where it is associated with serious complications, including cardiovascular events and respiratory distress. The limited effectiveness of current pharmacological treatments for nicotine dependence underscores the urgent need for innovative and effective therapeutic approaches. Recent studies have shown that ivermectin, an antiparasitic agent, modulates the GABAergic, glutamatergic, and purinergic systems, which are implicated in the pathophysiology of addiction. This study aimed to examine the effects of ivermectin on the acquisition, extinction, and reinstatement of nicotine dependence in mice, utilizing the conditioned place preference (CPP) test, a widely recognized methodology in drug addiction research. Ivermectin (1 and 5 mg/kg, i.p.) was co-administered with nicotine (0.5 mg/kg, i.p.) over three consecutive days during the acquisition phase of nicotine dependence. In a separate experiment, the influence of ivermectin on the reinstatement of nicotine-induced CPP was assessed following an extinction period, using a single nicotine priming injection (0.1 mg/kg). Results indicated that ivermectin (1 and 5 mg/kg) significantly reduced the development of nicotine dependence (p < 0.05). Furthermore, ivermectin (5 mg/kg) facilitated the extinction of nicotine-induced CPP (p < 0.01) and attenuated the reinstatement of nicotine-induced CPP triggered by a priming dose of nicotine (p < 0.01). In contrast, administration of the lower dose of ivermectin (1 mg/kg) did not yield statistically significant effects on either the extinction or reinstatement phases (p > 0.05). Additionally, nicotine administration, alone or in combination with ivermectin at the tested doses, did not produce significant changes in motor coordination or locomotor activity. These findings suggest that ivermectin may attenuate both the acquisition and reinstatement of nicotine-induced CPP while facilitating the extinction of nicotine dependence. Collectively, the results indicate that ivermectin holds potential as a therapeutic agent in the treatment of nicotine addiction.
- 26 September 2025
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 26 (3) , 490-498
Open AccessIvermectin attenuates nicotine-induced reward-like behaviors in mice
Nicotine addiction poses a significant public health threat, particularly within the realm of emergency medicine, where it is associated with serious complications, including cardiovascular events and respiratory distress. The limited effectiveness of current pharmacological treatments for nicotine dependence underscores the urgent need for innovative and effective therapeutic approaches. Recent studies have shown that ivermectin, an antiparasitic agent, modulates the GABAergic, glutamatergic, and purinergic systems, which are implicated in the pathophysiology of addiction. This study aimed to examine the effects of ivermectin on the acquisition, extinction, and reinstatement of nicotine dependence in mice, utilizing the conditioned place preference (CPP) test, a widely recognized methodology in drug addiction research. Ivermectin (1 and 5 mg/kg, i.p.) was co-administered with nicotine (0.5 mg/kg, i.p.) over three consecutive days during the acquisition phase of nicotine dependence. In a separate experiment, the influence of ivermectin on the reinstatement of nicotine-induced CPP was assessed following an extinction period, using a single nicotine priming injection (0.1 mg/kg). Results indicated that ivermectin (1 and 5 mg/kg) significantly reduced the development of nicotine dependence (p < 0.05). Furthermore, ivermectin (5 mg/kg) facilitated the extinction of nicotine-induced CPP (p < 0.01) and attenuated the reinstatement of nicotine-induced CPP triggered by a priming dose of nicotine (p < 0.01). In contrast, administration of the lower dose of ivermectin (1 mg/kg) did not yield statistically significant effects on either the extinction or reinstatement phases (p > 0.05). Additionally, nicotine administration, alone or in combination with ivermectin at the tested doses, did not produce significant changes in motor coordination or locomotor activity. These findings suggest that ivermectin may attenuate both the acquisition and reinstatement of nicotine-induced CPP while facilitating the extinction of nicotine dependence. Collectively, the results indicate that ivermectin holds potential as a therapeutic agent in the treatment of nicotine addiction.
- Open Access
- 2 August 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (3) , 202-238
A Comprehensive Review of the Pharmacological, Therapeutic, and Toxicological Properties of Boric Acid and Other Boron-Containing Compounds: Current Landscape and Future Perspectives
The aim. In this review, information obtained through a comprehensive scan of scientific resources on recent developments in the field of health regarding boric acids and BCCs is brought together, and current and future perspectives are presented.Matherial and methods. The literature studies on boron were collected using multiple databases (WOS, PubMed, Scopus, Science Direct, SciVerse, SciELO, Cochrane Library, Embase and Google Scholar). The health effects of boric acids and BCCs used in preclinical and clinical studies were systematically compiled.Results and conclusion. Different natural and synthetic boron-containing compounds (BCCs) are increasingly used in the healthcare sector. To date, five BCCs drugs (bortezomib, crisaborole, ixazomib, tavaborole and vaborbactam) have been approved by the Food and Drug Administration, for diverse clinical applications. It is also understood that more than ten boron-based compounds (alabostat, sodium borocaptate, voromycin, TOL-463 and others) are being investigated in different clinical trial phases. In addition, it is seen that clinical studies are continuing for combinations of various drugs with BCCs for use in new indications. In addition, it is observed that boron and boron-containing compounds are widely used as supplements. This review also provides an overview of recent advances in the pharmacological activities of boric acids and BCCs, including antioxidant, anti-inflammatory, anti-atherosclerotic, anticancer, antimicrobial, antiparasitic, antiviral, antiprotozoal, cardioprotective, hepatoprotective, neuroprotective, osteoprotective, antidiabetic, anti-apoptotic, anti-obesity, ferroptosis properties, effects on immune system, antiepileptic, anti-Parkinson, and anti-Alzheimer’s activities and the mechanisms of action involved, obtained from both in vitro and in vivo studies.
- 2 August 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (3) , 202-238
Open AccessA Comprehensive Review of the Pharmacological, Therapeutic, and Toxicological Properties of Boric Acid and Other Boron-Containing Compounds: Current Landscape and Future Perspectives
The aim. In this review, information obtained through a comprehensive scan of scientific resources on recent developments in the field of health regarding boric acids and BCCs is brought together, and current and future perspectives are presented.Matherial and methods. The literature studies on boron were collected using multiple databases (WOS, PubMed, Scopus, Science Direct, SciVerse, SciELO, Cochrane Library, Embase and Google Scholar). The health effects of boric acids and BCCs used in preclinical and clinical studies were systematically compiled.Results and conclusion. Different natural and synthetic boron-containing compounds (BCCs) are increasingly used in the healthcare sector. To date, five BCCs drugs (bortezomib, crisaborole, ixazomib, tavaborole and vaborbactam) have been approved by the Food and Drug Administration, for diverse clinical applications. It is also understood that more than ten boron-based compounds (alabostat, sodium borocaptate, voromycin, TOL-463 and others) are being investigated in different clinical trial phases. In addition, it is seen that clinical studies are continuing for combinations of various drugs with BCCs for use in new indications. In addition, it is observed that boron and boron-containing compounds are widely used as supplements. This review also provides an overview of recent advances in the pharmacological activities of boric acids and BCCs, including antioxidant, anti-inflammatory, anti-atherosclerotic, anticancer, antimicrobial, antiparasitic, antiviral, antiprotozoal, cardioprotective, hepatoprotective, neuroprotective, osteoprotective, antidiabetic, anti-apoptotic, anti-obesity, ferroptosis properties, effects on immune system, antiepileptic, anti-Parkinson, and anti-Alzheimer’s activities and the mechanisms of action involved, obtained from both in vitro and in vivo studies.
- Open Access
- 8 April 2025
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 29 (2) , 561-584
Pharmacological, medicinal and biological properties of flavonoids: A comprehensive review
Plant-based phytochemicals are currently being used to prevent and treat several diseases. Flavonoids are plant-based compounds that are widely found in the plant kingdom, which contain the benzopyrone ring, and possess various biological activities. To date, approximately more than 6000 different flavonoids have been identified and classified as flavones, flavanones, flavanols, isoflavones, anthocyanidins, and catechins. Many in vitro and in vivo experimental studies were published on the use of flavonoids in different conditions. Antioxidant, antiinflammatory, antibacterial, antifungal, antiviral, antihypertensive, antihyperlipidemic, antithrombotic, antiasthma, antiallergic, antidiabetic, antiobesity, antiarthritis, antiulcer, hepatoprotective, osteoprotective, immunomodulation, anticancer, antiaging, neuroprotective, antiaddictive, antiparkinsonian, antiepileptic, anxiolytics and antidepressant are among the primary pharmacological properties of these compounds. Despite a wide range of the ongoing research on the potential health benefits of flavonoids, the U.S. FDA (and similar organizations) has not approved any flavonoid compounds for therapeutic use. However, these compounds are available as nutritional supplements in various dosage forms. In this review, we used the databases like PubMed, Web of Science, ScienceDirect, Scopus, ResearchGate and Google Scholar to find the best-matched information about flavonoids’ pharmacological, medicinal and biological properties to elucidate the therapeutic potential as well as their side effects. A comprehensive systematic literature review was carried out to achieve the main goal of this study.
- 8 April 2025
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 29 (2) , 561-584
Open AccessPharmacological, medicinal and biological properties of flavonoids: A comprehensive review
Plant-based phytochemicals are currently being used to prevent and treat several diseases. Flavonoids are plant-based compounds that are widely found in the plant kingdom, which contain the benzopyrone ring, and possess various biological activities. To date, approximately more than 6000 different flavonoids have been identified and classified as flavones, flavanones, flavanols, isoflavones, anthocyanidins, and catechins. Many in vitro and in vivo experimental studies were published on the use of flavonoids in different conditions. Antioxidant, antiinflammatory, antibacterial, antifungal, antiviral, antihypertensive, antihyperlipidemic, antithrombotic, antiasthma, antiallergic, antidiabetic, antiobesity, antiarthritis, antiulcer, hepatoprotective, osteoprotective, immunomodulation, anticancer, antiaging, neuroprotective, antiaddictive, antiparkinsonian, antiepileptic, anxiolytics and antidepressant are among the primary pharmacological properties of these compounds. Despite a wide range of the ongoing research on the potential health benefits of flavonoids, the U.S. FDA (and similar organizations) has not approved any flavonoid compounds for therapeutic use. However, these compounds are available as nutritional supplements in various dosage forms. In this review, we used the databases like PubMed, Web of Science, ScienceDirect, Scopus, ResearchGate and Google Scholar to find the best-matched information about flavonoids’ pharmacological, medicinal and biological properties to elucidate the therapeutic potential as well as their side effects. A comprehensive systematic literature review was carried out to achieve the main goal of this study.
- Open Access
- 7 January 2025
- Published by Warszawski Uniwersytet Medyczny in Prospects in Pharmaceutical Sciences
- No. 2025 (Earl
ALPHA-LIPOIC ACID IN PHARMACEUTICAL DEVELOPMENT: A COMPREHENSIVE REVIEW OF ITS THERAPEUTIC POTENTIAL AND MOLECULAR MECHANISMS
Alpha-lipoic acid (ALA), also known as thioctic acid is a lipid acid with strong biological activity synthesised from octanoic acid in prokaryotic and eukaryotic microorganisms, plants, and animals. It is gaining attention for its potential therapeutic benefits for a wide range of health problems. A comprehensive systematic literature review on ALA has been performed without temporal restrictions utilizing the PubMed, Scopus, Embase, ScienceDirect, SciELO, and SciVerse databases. Different in vitro, in vivo, and clinical studies have demonstrated numerous potent pharmacological activities of ALA, including antioxidant, anti-inflammatory, antimicrobial, anti-Alzheimer, antiepileptic, antiparkinsonian, anxiolytic, effects on schizophrenia, neuroprotective, antidiabetic, antiallergic, anticancer, anti-osteoporosis, cardioprotective, hepatoprotective, anti-obesity, anti-aging, reproductive system, and so on. Although dietary supplements (tablets, capsules, etc.) containing ALA are available due to their various biological activities, there are no Food and Drug Administration (FDA) and European Medicines Agency (EMA)-approved over-the-counter (OTC) ALA drugs in the world. Pharmacokinetically, ALA has an oral bioavailability of approximately 30% due to its brief blood half-life, significant presystemic clearance, and hepatic first-pass metabolism. However, the use of different innovative formulations has greatly enhanced ALA bioavailability. The data obtained show that ALA liquid formulations have higher plasma concentrations and therefore bioavailability compared to solid dosages. These innovative approaches hold promise for the development of improved ALA-based treatments across a broad spectrum of health conditions.
- 7 January 2025
- Published by Warszawski Uniwersytet Medyczny in Prospects in Pharmaceutical Sciences
- No. 2025 (Earl
Open AccessALPHA-LIPOIC ACID IN PHARMACEUTICAL DEVELOPMENT: A COMPREHENSIVE REVIEW OF ITS THERAPEUTIC POTENTIAL AND MOLECULAR MECHANISMS
Alpha-lipoic acid (ALA), also known as thioctic acid is a lipid acid with strong biological activity synthesised from octanoic acid in prokaryotic and eukaryotic microorganisms, plants, and animals. It is gaining attention for its potential therapeutic benefits for a wide range of health problems. A comprehensive systematic literature review on ALA has been performed without temporal restrictions utilizing the PubMed, Scopus, Embase, ScienceDirect, SciELO, and SciVerse databases. Different in vitro, in vivo, and clinical studies have demonstrated numerous potent pharmacological activities of ALA, including antioxidant, anti-inflammatory, antimicrobial, anti-Alzheimer, antiepileptic, antiparkinsonian, anxiolytic, effects on schizophrenia, neuroprotective, antidiabetic, antiallergic, anticancer, anti-osteoporosis, cardioprotective, hepatoprotective, anti-obesity, anti-aging, reproductive system, and so on. Although dietary supplements (tablets, capsules, etc.) containing ALA are available due to their various biological activities, there are no Food and Drug Administration (FDA) and European Medicines Agency (EMA)-approved over-the-counter (OTC) ALA drugs in the world. Pharmacokinetically, ALA has an oral bioavailability of approximately 30% due to its brief blood half-life, significant presystemic clearance, and hepatic first-pass metabolism. However, the use of different innovative formulations has greatly enhanced ALA bioavailability. The data obtained show that ALA liquid formulations have higher plasma concentrations and therefore bioavailability compared to solid dosages. These innovative approaches hold promise for the development of improved ALA-based treatments across a broad spectrum of health conditions.
- 2 January 2024
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 50 (1) , 75-83
Effects of fisetin on ethanol-induced rewarding properties in mice
Background: Alcohol use disorder (AUD) is a chronic relapsing disorder associated with compulsive drinking of alcohol. Natural flavonoid fisetin affects a variety of transmitter systems relevant to AUD, such as aminobutyric acid, N-methyl-D-aspartate, and dopamine, as well as peroxisome proliferator-activated receptors.Objectives: This study investigated fisetin's impact on the motivational properties of ethanol using conditioned place preference (CPP) in mice (n = 50).Methods: Mice were conditioned with ethanol (2 g/kg, i.p.) or saline on alternating days for 8 consecutive days and were given intragastric (i.g.) fisetin (10, 20, or 30 mg/kg, i.g.), 45 min before ethanol conditioning. During extinction, physiological saline was injected to the control and ethanol groups, and fisetin was administered to the fisetin groups. To evaluate the effect of fisetin on the reinstatement of ethanol-induced CPP, fisetin was given 45 min before a priming dose of ethanol (0.4 g/kg, i.p.; reinstatement test day).Results: Fisetin decreased the acquisition of ethanol-induced CPP (30 mg/kg, p < .05) and accelerated extinction (20 and 30 mg/kg, p < .05). Furthermore, fisetin attenuated reinstatement of ethanol-induced CPP (30 mg/kg, p < .05).Conclusions: Fisetin appears to diminish the rewarding properties of ethanol, as indicated by its inhibitory effect and facilitation of extinction in ethanol-induced CPP. These findings imply a potential therapeutic application of fisetin in preventing ethanol-seeking behavior, promoting extinction, and reducing the risk of relapse.
- 2 January 2024
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 50 (1) , 75-83
Effects of fisetin on ethanol-induced rewarding properties in mice
Background: Alcohol use disorder (AUD) is a chronic relapsing disorder associated with compulsive drinking of alcohol. Natural flavonoid fisetin affects a variety of transmitter systems relevant to AUD, such as aminobutyric acid, N-methyl-D-aspartate, and dopamine, as well as peroxisome proliferator-activated receptors.Objectives: This study investigated fisetin's impact on the motivational properties of ethanol using conditioned place preference (CPP) in mice (n = 50).Methods: Mice were conditioned with ethanol (2 g/kg, i.p.) or saline on alternating days for 8 consecutive days and were given intragastric (i.g.) fisetin (10, 20, or 30 mg/kg, i.g.), 45 min before ethanol conditioning. During extinction, physiological saline was injected to the control and ethanol groups, and fisetin was administered to the fisetin groups. To evaluate the effect of fisetin on the reinstatement of ethanol-induced CPP, fisetin was given 45 min before a priming dose of ethanol (0.4 g/kg, i.p.; reinstatement test day).Results: Fisetin decreased the acquisition of ethanol-induced CPP (30 mg/kg, p < .05) and accelerated extinction (20 and 30 mg/kg, p < .05). Furthermore, fisetin attenuated reinstatement of ethanol-induced CPP (30 mg/kg, p < .05).Conclusions: Fisetin appears to diminish the rewarding properties of ethanol, as indicated by its inhibitory effect and facilitation of extinction in ethanol-induced CPP. These findings imply a potential therapeutic application of fisetin in preventing ethanol-seeking behavior, promoting extinction, and reducing the risk of relapse.
- 22 February 2023
- Published by Taylor & Francis in International Journal of Environmental Health Research
- Vol. 33 (5) , 529-540
Oleanolic acid suppresses pentylenetetrazole-induced seizure in vivo
The aim of this study was to investigate the protective effects of triterpene oleanolic acid on the brain tissue of mice with pentylenetetrazole (PTZ)-induced epileptic seizures. Male Swiss albino mice were randomly separated into five groups as the PTZ, control, and oleanolic acid (10, 30, and 100 mg/kg) groups. PTZ injection was seen to cause significant seizures compared with the control group. Oleanolic acid significantly prolonged the latency to onset of myoclonic jerks and the duration of clonic convulsions, and decreased mean seizure scores following PTZ administration. Pretreatment with oleanolic acid also led to an increase in antioxidant enzyme activity (CAT and AChE) and levels (GSH and SOD) in the brain. The data obtained from this study support oleanolic acid may have anticonvulsant potential in PTZ-induced seizures, prevent oxidative stress and protect against cognitive disturbances. These results may provide useful information for the inclusion of oleanolic acid in epilepsy treatment.
- 22 February 2023
- Published by Taylor & Francis in International Journal of Environmental Health Research
- Vol. 33 (5) , 529-540
Oleanolic acid suppresses pentylenetetrazole-induced seizure in vivo
The aim of this study was to investigate the protective effects of triterpene oleanolic acid on the brain tissue of mice with pentylenetetrazole (PTZ)-induced epileptic seizures. Male Swiss albino mice were randomly separated into five groups as the PTZ, control, and oleanolic acid (10, 30, and 100 mg/kg) groups. PTZ injection was seen to cause significant seizures compared with the control group. Oleanolic acid significantly prolonged the latency to onset of myoclonic jerks and the duration of clonic convulsions, and decreased mean seizure scores following PTZ administration. Pretreatment with oleanolic acid also led to an increase in antioxidant enzyme activity (CAT and AChE) and levels (GSH and SOD) in the brain. The data obtained from this study support oleanolic acid may have anticonvulsant potential in PTZ-induced seizures, prevent oxidative stress and protect against cognitive disturbances. These results may provide useful information for the inclusion of oleanolic acid in epilepsy treatment.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 59
Resveratrol inhibits nicotine-induced conditioned place preference in mice
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 59
Open AccessResveratrol inhibits nicotine-induced conditioned place preference in mice
- 27 October 2022
- Published by Academician Publishing
Geriatrik Onkoloji
Onkoloji alanındaki tüm dünyanın yakın takip ettiği bilimsel gelişmeler ışığında günümüzde artık sistemik kemoterapi gibi konvansiyonel tedaviler yerlerini büyük ölçüde immünoterapi, moleküler hedefli ilaçlar ve gen tedavilerine bırakmaya başlamıştır. Bu tedavi seçeneklerinin her biri ayrı ayrı vazgeçilmez önemde olup tedavi seçimleri ve sıralamaları bireyselleştirilmiş tedavi stratejileri sayesinde her hastaya özgü bir şekilde planlanmaktadır. Tedavilerin bireyselleştirilmesi hususunda kuşkusuz yaş faktörünün önemi büyüktür ve tedavi kararlarında geriatrik popülasyon için seçilecek tedavi modalitesinin belirlenmesi oldukça hassas bir konudur. Zira tedavi seçeneklerinin herbirinin geriatrik popülasyonda kullanım şemaları, yan etki dağılımları ve yönetimleri farklılıklar göstermekte olup günlük pratiğimizde azımsanmayacak sıklıkta karşılaştığımız problemlerdendir.
- 27 October 2022
- Published by Academician Publishing
Geriatrik Onkoloji
Onkoloji alanındaki tüm dünyanın yakın takip ettiği bilimsel gelişmeler ışığında günümüzde artık sistemik kemoterapi gibi konvansiyonel tedaviler yerlerini büyük ölçüde immünoterapi, moleküler hedefli ilaçlar ve gen tedavilerine bırakmaya başlamıştır. Bu tedavi seçeneklerinin her biri ayrı ayrı vazgeçilmez önemde olup tedavi seçimleri ve sıralamaları bireyselleştirilmiş tedavi stratejileri sayesinde her hastaya özgü bir şekilde planlanmaktadır. Tedavilerin bireyselleştirilmesi hususunda kuşkusuz yaş faktörünün önemi büyüktür ve tedavi kararlarında geriatrik popülasyon için seçilecek tedavi modalitesinin belirlenmesi oldukça hassas bir konudur. Zira tedavi seçeneklerinin herbirinin geriatrik popülasyonda kullanım şemaları, yan etki dağılımları ve yönetimleri farklılıklar göstermekte olup günlük pratiğimizde azımsanmayacak sıklıkta karşılaştığımız problemlerdendir.